BD's stock gains on launch of rapid COVID-19 diagnostic test
Shares of Becton Dickinson & Co. (BDX) gained 3.6% in premarket trading on Monday after the diagnostics company announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes. It's the third BD COVID-19 diagnostic test to receive emergency use authorization from the Food and Drug Administration during the pandemic. "This will be a game-changer for frontline health care workers and their patients to be able to access a quick diagnostic test for COVID-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers and doctors' offices," Dave Hickey, president of BD's integrated diagnostic solutions business, said in a news release. BD's stock is down 9.9% year-to-date, while the S&P 500 has declined 3.1%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
July 06, 2020 07:43 ET (11:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.